[비즈한국] Daewoong Pharmaceutical069620 is accelerating its leap beyond new drug development and pharmaceutical sales to become a digital healthcare platform company. Moving beyond the role of a wearable device distributor, the company revealed its determination to build a 24-hour health monitoring system that provides integrated, cutting-edge medical solutions.
Park Hyung-chul, Head (Executive Director) of Daewoong Pharmaceutical's ETC Marketing Division, said at a press conference announcing its digital healthcare business vision held at the JW Marriott Dongdaemun Square in Jongno-gu, Seoul, on the morning of the 23rd, “While patient conditions were intermittently checked by relying on the dedication of medical staff until just a few years ago, starting in 2026, we will present a 24-hour national health monitoring system that connects hospitals, local communities, and homes into one for preemptive management.”
This means that while existing digital healthcare operated only within hospitals, the scope will now be expanded beyond the hospital walls to include patients who have returned home or are undergoing rehabilitation. Park explained, “We will connect medical care to every household so that patient care is not interrupted outside the hospital.”
To achieve this, Daewoong Pharmaceutical is determined to showcase an integrated platform rather than being limited to the introduction of individual technologies. Daewoong Pharmaceutical has introduced and supplied wearable ECG monitors like ‘MobiCare’ and ring-type blood pressure monitors like ‘CartBP’ in the domestic market. Park stated, “Although there has been significant technological advancement, it has not been organically connected. Daewoong Pharmaceutical will take on the role of implementing these in a way that can be practically utilized in medical settings.”
The ‘ThynC’ system from partner company Seers Technology458870 is expected to play a core role in realizing Daewoong Pharmaceutical’s vision. ThynC is a smart bedside monitoring system that analyzes vital signs collected via wearable biosensors attached to the patient's body using clinically validated AI algorithms. The service is expected to be upgraded by adding new digital healthcare solutions to ThynC.
Currently, it can detect changes in blood pressure, ECG, oxygen saturation, and body temperature, but Seers Technology plans to expand its monitoring items. A Seers Technology representative said, “We are preparing to expand the monitoring areas to 8–9 categories, including blood glucose, sepsis, and IV fluids.”
At the press conference, an area was set up to experience various devices: the ophthalmic diagnostic equipment ‘Optina’ and ‘Vishee’, the pulmonary function testing device ‘SpiroKit’ (which detects COPD and asthma by breathing in and out), i-COOP's continuous glucose monitor ‘CGM Live’, Sky Labs' ring-type blood pressure monitor ‘Cart-ON’, and PuzzleAI's AI-based voice recognition medical record solution ‘CLNote’.
For ‘CGM Live’, which is expected to be integrated into ThynC in May, blood glucose levels could be checked every 15 minutes through an app installed on a smartphone after attaching a sensor to the back of the upper arm. An i-COOP representative explained, “One hour after attaching the sensor, hospitals and patients can see glucose levels for 14 days without additional blood draws. It is also used by hospitalized patients or diabetic patients who need blood glucose checks to monitor their own levels.”
Daewoong Pharmaceutical has been supplying ThynC to medical institutions since 2024. ThynC first obtained insurance coverage last February and, as of the 9th, is being used in a total of 15,000 beds across 162 hospitals nationwide.
In the field, it is evaluated that ThynC has enhanced the quality of patient care by reducing the workload on medical staff. Lee Gyu-min, President of the Association of Nurses at Small and Medium-sized Hospitals, explained, “Previously, nurses had to visit rooms to manually check vital signs and patient conditions one by one, but after the introduction of ThynC, they can check real-time patient status through a central monitor, which has greatly increased efficiency. This creates an environment where nurses can concentrate on patients who need intensive care.”
Daewoong Pharmaceutical’s digital healthcare business is not expected to be limited to Korea. The judgment is that while global healthcare companies like GE, Philips, and Johnson & Johnson (J&J) are leading the field, Daewoong has a competitive edge because its solutions have been verified in Korea, which has excellent network infrastructure. A Seers Technology representative said, “We plan to conduct a Proof of Concept (PoC) in the UAE between March and April, and we are also working to expand into Colombia, Thailand, Cambodia, Mongolia, and Kazakhstan.”
Daewoong Pharmaceutical shows strong confidence in the growth of its digital healthcare business, setting this year’s revenue target at six times last year’s level. Park said, “I feel a sense of responsibility in significantly expanding the digital healthcare market. We can achieve 300 billion won in revenue this year with just the products already commercialized in the market.”